Clinical Trial Update: A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating intravenous HRS9432 for the treatment of candidemia and/or invasive candidiasis and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidemia
• Invasive Candidiasis

Drugs mentioned

• HRS9432 (HRS9432)

Snippet

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Conditions: Patients With Candidemia and/or Invasive Candidiasis | Phase 2 | Status: RECRUITING